Across TCGA pan-cancer cohorts, CENPBD1P1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CENPBD1P1 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CENPBD1P1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CENPBD1P1 expression acts as an unfavorable survival marker.
UCEC and SARC are the cancer types where CENPBD1P1 Mutation most reproducibly stratifies survival.